

# Healthy Heart

Volume-6 | Issue-66 | May 5, 2015

Price : ₹ 5/-

**Honorary Editor :**  
Dr. Milan Chag



## From the Desk of Hon. Editor:

Dear Friends,

Atrial Fibrillation (AF) is the most common arrhythmia in clinical practice affecting approximately 9 million people in US and Europe and may be an equal number of patients in the rest of the world. AF increases the risk of stroke by 5 fold and to decrease this risk, such patients need long-term Oral AntiCoagulant (OAC) therapy if stroke risk is intermediate or high as assessed by CHA2DS2-VASc score. For patients who cannot tolerate OAC or has suboptimal INR control or has contraindications for that, there is new ray of hope in form of percutaneously insertable novel left atrial appendage occluding device which is now approved by US-FDA for suitable patients.

- Dr. Milan Chag

## Left Atrial Appendage Closure: A Novel, Approved Therapy for Atrial Fibrillation and Stroke Risk Reduction

### What is risk of stroke in patients with Atrial Fibrillation?

Atrial fibrillation is the most common arrhythmia treated in clinical practice. Patients with AF have a 5 times increased risk of stroke and two fold increase risk of all-cause mortality (Figure 1). AF-related strokes are more frequently fatal and disabling. Approximately half of acute stroke victims will die or live with a significant disability, which may result in institutional care.

The major goal of therapy is to prevent

thrombo-embolic complications such as stroke. Warfarin is more effective than Aspirin to prevent this. However, despite its proven efficacy, long-term warfarin therapy is not well-tolerated by some patients and carries a significant risk for bleeding complications.

Therefore, it is useful to risk stratify patients with AF to identify appropriate candidates for long-term oral anticoagulant therapy. Simple and most widely used risk score is CHA2DS2-VASc score (Figure 2). If score is 2 or more,




Figure-1

### Cardiologists

Dr. Ajay Naik (M) +91-98250 82666 Dr. Keyur Parikh (M) +91-98250 26999  
Dr. Satya Gupta (M) +91-99250 45780 Dr. Milan Chag (M) +91-98240 22107  
Dr. Vineet Sankhla (M) +91-99250 15056 Dr. Urmil Shah (M) +91-98250 66939  
Dr. Jayaram Prajapati (M) +91-82386 44222 Dr. Hemang Baxi (M) +91-98250 30111  
Dr. Gunvant Patel (M) +91-98240 61266 Dr. Anish Chandarana (M) +91-98250 96922

### Congenital & Structural Heart Disease Specialist

Dr. Kashyap Sheth (M) +91-99246 12288 Dr. Milan Chag (M) +91-98240 22107  
Dr. Divyesh Sadadiwala (M) +91-8238339980

### Cardiothoracic & Vascular Surgeons

Dr. Dhaval Naik (M) +91-90991 11133  
Dr. Manan Desai (M) +91-96385 96669  
Dr. Dhiren Shah (M) +91-98255 75933

### Pediatric & Structural Heart Surgeons

Dr. Shaunak Shah (M) +91-98250 44502

### Cardiovascular, Thoracic & Thoracoscopic Surgeon

Dr. Pranav Modi (M) +91-99240 84700

### Cardiac Anaesthetists

Dr. Hiren Dholakia (M) +91-95863 75818  
Dr. Chintan Sheth (M) +91-91732 04454  
Dr. Niren Bhavsar (M) +91-98795 71917

### Neonatologist and Pediatric Intensivist

Dr. Amit Chitaliya (M) +91-90999 87400

### Cardiac Electrophysiologist

Dr. Ajay Naik (M) +91-98250 82666  
Dr. Vineet Sankhla (M) +91-99250 15056

## Thrombo-embolic risk : CHA<sub>2</sub> DS<sub>2</sub>-VASc Score

Letter	Risk factor	Score
C	Congestive heart failure/LV dysfunction	1
H	Hypertension	1
A <sub>2</sub>	Age ≥ 75	2
D	Diabetes mellitus	1
S <sub>2</sub>	Stroke/TIA/thrombo-embolism	2
V	Vascular disease	1
A	Age 65–74	1
Sc	Sex category (i.e. female sex)	1
TOTAL (maximum 9)		
Stroke rate (%/year) by score	0	0.0
	1	1.3
2	2	2.2
	3	3.2
4	4	4.0
	5	6.7
6	6	9.8
	7	9.6
8	8	6.7
	9	15.2

Lip GY et al, Chest 2010; 137(2): 263–72  
Camm AJ et al, Eur Heart J 2010; 31, 2369–2429

Figure-2

## Bleeding risk : HASBLED Score

Letter	Clinical characteristic	Points awarded
H	Hypertension	1
A	Abnormal renal and liver function (1 point each)	1 or 2
S	Stroke	1
B	Bleeding	1
L	Labile INRs	1
E	Eldery (e.g. age ≥ 65 years)	1
D	Drugs or alcohol (1 point each)	1 or 2
TOTAL (maximum 9)		
Bleeds per 100 patient-years by score	0	1.13
	1	1.02
2	2	1.88
	3	3.74
4	4	8.70

Pisters R, et al. Chest 2010; 138:1093-100  
European Heart Journal 2012 - doi:10.1093/eurheartj/ehs253

Figure-3

Total Score : CHA <sub>2</sub> DS <sub>2</sub> -VASc Score	Anticoagulation therapy options
0 (low stroke risk)	No antithrombotic therapy (or aspirin 75-325 mg daily)
1 (moderate)	Either DOAC or warfarin at an international normalized ratio (INR) of 2.3-3.0
≥2 (high)	Either DOAC or warfarin at INR 2.0-3.0

patient is at high risk and needs oral anti-coagulant. Patients with score 0 (Low risk) may be kept on Aspirin alone while those with score 1 (Intermediate risk) may be given Aspirin or OAC. Bleeding risk may be assessed by HASBLED score (Figure 3) but prevention of thromboembolism has more priority than bleeding risk.

### AF related Stroke Risk Treatment Option (Figure-4 & 5):

- ◆ AF is projected to increase as population ages.
- ◆ Prevalence is estimated to at least double in the next 50 years as population ages.

- ◆ In non-valvular AF, over 90% of stroke-causing clots that come from the left atrium are formed in the left atrial appendage (LAA).
- ◆ 50% of AF-related strokes occur under the age of 75.
- ◆ <50% of patients eligible for warfarin are NOT being treated (tolerance/compliance).
- ◆ Lifestyle limitations when taking warfarin include high risk of bleeding, negative interactions with food and drugs, serious side effects that are often difficult to tolerate, and requires frequent and ongoing monitoring.
- ◆ Left atrial appendage closure is an alternative to medication. Local

therapy with left atrial appendage closure by percutaneous implantable device like WATCHMAN or Amplatzer vascular plug is an option to reduce the risk of stroke in patients with non-valvular atrial fibrillation. It is designed to avoid the embolization of thrombi that may form in the left atrial appendage (LAA).

### Indications: Who should have LAA device closure? (Figures : 6-9)

Left Atrial Appendage Closure Technology is intended to prevent thrombus embolization from the left atrial appendage and reduce the risk of life-threatening bleeding events in




Figure-4




Figure-5

patients with non valvular atrial fibrillation who are eligible for anticoagulation therapy or who have a contraindication to anti-coagulation therapy (Figure 4).

### Benefits of LAA Closure:

- ◆ Stroke risk reduction
- ◆ Long term anticoagulation therapy cessation
- ◆ Better quality of life

### Post-procedure:

As the procedure is minimally invasive patient recovery takes about 24 hours. After the device has been implanted, patient should receive Warfarin (or other OACs) for 45 days, to facilitate device

endothelialisation. A follow-up trans-oesophageal echocardiography will be performed at 45 days. At this stage, physician may decide to discontinue Warfarin therapy and prescribe Clopidogrel (75mg) and Aspirin (81-325mg) until completion of the 6 months

visit, from which point aspirin alone should be continued. Physicians may prescribe clopidogrel and aspirin daily dose for up to six months to the patients contraindicated to anticoagulation therapy. These patients should remain on aspirin indefinitely.




Figure-6



Figure-7






Figure-8




Figure-9




Figure-10




Figure-11

## Safety, Efficacy and Mortality Data (Figure 6-11)

- ◆ Proven implant safety profile demonstrating a 95% implant success in the hands of both new and experienced operators, as well as a declining procedural complications rate to less than 5% in later trials.
- ◆ 40% reduction of stroke, systemic embolism, cardiovascular/unexplained death at 4 years in PROTECT-AF study

- ◆ 60% reduction in CV-death compared to Warfarin at 4 years in PROTECT-AF study
- ◆ 34% reduction in All Cause Death compared to Warfarin at 4 years in PROTECT-AF study
- ◆ FDA has recently approved Watchman device for LAA closure

**Courtesy :** Some of figures, charts and information are taken from Boston Scientific Inc.

## CLC | online



## CIMS Learning Center shortly launches **CLC online**

CLC online will comprise of interesting and innovative surgeries and procedures performed in the CIMS OT and Cath Lab.

To ensure that you receive these updates, please email your Name and Email ID along with other demographics details (Address, Contact No.) on [clc@cimshospital.org](mailto:clc@cimshospital.org)

## First in Versa-HD in India

### FFF (Flattening Filter- Free) for Radiotherapy at CIMS

A recent milestone achieved by CIMS Cancer Center in Radiotherapy is the AERB approval to use FFF (Flattening Filter- Free) for clinical use. By removing the flattening filter from the linear accelerator, greater dose rate can be achieved due to the physiologic property of flat beam. Advanced treatment like SRS (Stereotactic Radio Surgery) SRT (Stereotactic Radio Therapy) and SBRT (Stereotactic Body Radiation Therapy for Lungs and Prostate) with use of state of art planning system can now be used to modulate non-flat, high dose rate beams to achieve highly conformal dose distributions with a reduced treatment time.



International  
Centers  
of Excellence  
2014-2015

**American College of Cardiology (ACC)**  
(Leading Institute of the World)  
**certifies CIMS Hospital as a**



## ACC - Center of Excellence

Amongst the first in World and only one in India

for high-standards of medical practice and dedication  
in providing quality cardiovascular care



**CIMS Express (Cardiology) - Same day appointment for new patient / second opinion**

**Call on 98250 66661, 079-3010 1008 (9 am to 5 pm) 98244 50000 (24 x 7)**

**CIMS Hospital : Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060.**



info@cims.me | www.cims.me

f/cimshospitals



## RENAL TRANSPLANT now at CIMS Hospital

with the backing of world class technology

A highly experienced and skilled renal transplant  
team with experience of over more than 1000 cases



**For appointment call:**

+91-79-3010 1200, 3010 1008 (M) +91-98250 66661

## CIMS welcomes the following as a part of their team

### Interventional Cardiologist

**Dr. Jayaram B. Prajapati**

DNB (Medicine), DNB (Cardiology)

(M) +91-82386 44222

(CIMS - Lions Cardiac Center, Mehsana)

### Interventional Paediatric Cardiologist

**Dr. Divyesh Sadadiwala**

MD (Peds.), FPC

(M) +91-8238339980

### Consultant Paediatrician & Neonatologist

**Dr. Snehal H. Patel**

MBBS, DNB (Paediatrics)

(M) +91-9998149794

## Management of pregnant patients coming for open heart surgery

### Introduction:

The incidence of heart disease in pregnant women is reported to vary from 1% to 4%. In low-income countries, 60-80% of the pregnant women with heart disease suffer from rheumatic heart disease and it is a major cause of death related to pregnancy. Indications for surgery using Cardio Pulmonary Bypass (CPB) during pregnancy include cardiac valve disease, prosthetic valve malfunction, cardiac myxoma, congenital heart disease, pulmonary embolism, aneurysm and coronary artery disease. Recent data suggests a maternal mortality rate similar (1.47%) to that associated with CPB in non-pregnant women, unless the surgery is emergent while fetal mortality is as high as 16-33%. Cardiac surgery in pregnant patients, as a result, must be limited to cases where medical management fails.

Recently, we have successfully managed a case of 26years old primigravida with 5.5 months of amenorrhea with twins fetus with ruptured sinus of valsalva into right ventricle and Ventricular Septal Defects (VSD). Patient has been operated successfully with repair of ruptured sinus of valsalva with VSD repair on CPB. Mother discharged with stable condition with live healthy twin fetus.

Success of surgery depend upon the timing (trimester) of surgery, perturbation of maternal cardiovascular system by the heart disease, concomitant maternal and fetal morbidities. Table 1 shows the predictors of maternal and fetal outcome according to the heart disease.

### Why it's a real challenge?

During pregnancy physiologically cardiac output increases by 40-50% with increase in plasma volume by 45% and heart rate

by 15-25%. The presence of maternal heart disease with these circulatory changes of pregnancy can result in decompensation and in death of the mother or fetus.

### Management:

There is no difference in surgical approach and management of a pregnant versus non pregnant patient coming for heart surgery. Anaesthesia and cardiopulmonary bypass management is the real challenge as at any given point of time uteroplacental insufficiency can result in fetal demise. So proper planning with multi disciplinary team approach including cardiologist, cardiac surgeon, cardiac anaesthesiologist, gynecologist and perfusionologist is upmost important

### Goals of anaesthesia and CPB management

- Infective endocarditis prophylaxis
- Avoid feto toxic drugs
- Be prepared for difficult intubation as airway edema with high vascularity
- Antiaspiration prophylaxis
- Avoid inferior ven caval compression by gravid uterus by left lateral tilt of 20-30 degree
- Fetal heart rate and uterine contraction monitoring (fig. 1)
- Maintain utero placental circulation
- On CPB maternal hematocrit >25%, High maternal oxygen saturation, Normothermia, High perfusion flow rates (>2.5 L/min/m<sup>2</sup>), High perfusion pressure (>70 mm of Hg), Minimize CPB time with Pulsatile flow (preferred but not mandatory)
- Adequate analgesia post operatively
- CPR in pregnancy is different than non pregnant patient
- At any given point of time maternal well being is given priority over fetus

**Table 1. Predictors of maternal and fetal outcome**

Low Risk	Moderate Risk	High Risk
Most commonly repaired lesions	Single ventricle	NYHA functional class >III
Uncomplicated left-to-right shunt	Systemic right ventricle	History of peripartum cardiomyopathy
Pulmonary stenosis	Uncorrected coarctation	Pulmonary hypertension
Pulmonary regurgitation	Unrepaired cyanotic lesions	Marfan syndrome with aortic size >4 mm
Aortic regurgitation	Use of anticoagulants	Severe left ventricular dysfunction
Mitral regurgitation, mitral valve prolapse	Mitral stenosis	
	Aortic stenosis	
	Left ventricular dysfunction	

NYHA = New York Heart Association

\*Adopted from a table in Dob and Yentis.\*

## Counseling of women with heart disease

- The counselling of cardiac patients about the risk of pregnancy should commence as soon as they become sexually active.
- Adequate advice concerning contraception should be offered.
- There is a significant risk of maternal cardiac decompensation and death during pregnancy and in the first month post partum in women with Eisenmenger's syndrome, severe pulmonary hypertension, severe aortic stenosis or left ventricular outflow tract obstruction, Marfan's syndrome with aortic dilation greater than 4 cm or symptomatic systemic ventricular dysfunction with an ejection fraction < 40%. These patients should be counseled against pregnancy.
- In general regurgitant and volume overloaded conditions are better tolerated than stenotic and pressure overloaded conditions.
- When a woman wants to get pregnant, clinical assessment including echocardiography, exercise testing and sometimes 24-hour ECG and MRI is indicated. Based on these data, risk assessment can be performed.
- When it is decided that the woman can carry on and attempt to get pregnant, each medicine that she is using should be reviewed: is it necessary to continue this




Figure1: fetal heart rate and uterine contraction monitoring

medication throughout pregnancy, or can it be safely discontinued, or should it be replaced by a safer alternative?

- A plan for cardiology and obstetric supervision during pregnancy must be made
- If pregnant patient requires cardiac surgeries, it should be performed during second trimester as first trimester is associated with organogenesis and third trimester is associated with risk of premature delivery.
- Many women with heart disease can go through pregnancy with few or no complications if managed by multidisciplinary team at tertiary care center.

## Primary Care Team for the patient

### Pediatric & Structural Heart Surgeon

**Dr. Shaunak Shah**  
+91-98250 44502

### Pediatric Cardiologists

<b>Dr. Kashyap Sheth</b> +91-99246 12288	<b>Dr. Divyesh Sadadiwala</b> +91-8238339980	<b>Dr. Milan Chag</b> +91-98240 22107
---	---	--

### CIMS Cardiac Anaesthetists Team

<b>Dr. Hiren Dholakia</b> +91-95863 75818	<b>Dr. Chintan Sheth</b> +91-91732 04454	<b>Dr. Niren Bhavsar</b> +91-98795 71917
--	---	---

### Pediatric Intensivists

<b>Dr. Amit Chitaliya</b> +91-90999 87400	<b>Dr. Snehal Patel</b> +91-9998149794
--	---

### Obstetrics and Gynecologist


**Dr. Sneha Baxi**  
+91-98255 07370

### CIMS Cardiac Perfusionist Team

<b>Ulhas Padiyar</b> +91-98983 57772	<b>Dhanyata Dholakia</b> +91-95864 49430	<b>Prashant Nair</b> +91-99789 84332
---	---	---

## TECHNOLOGICAL BREAKTHROUGH VALVE SURGERY AT CIMS

On April 3, 2015 Trans Aortic TAVR (Transcatheter Aortic Valve Replacement) was done for the first time in India on a 81 year old male patient with severe aortic stenosis, LVEF 25%, COPD, mild renal dysfunction and severe peripheral arterial disease. It was a very high risk case for an open heart procedure: so TAVR was decided upon. TAVR IS A HYBRID PROCEDURE where in cardiology catheter based technique and cardiac surgery beating heart technique are combined to give mortality and morbidity benefit to the patient. Because this patient had severe peripheral artery stenosis, through a small right thoracotomy a direct aortic puncture access was used and stent mounted aortic tissue valve was implanted



on beating heart. Post op recovery is good and LVEF has improved. This procedure was performed by Dr Dhiren Shah (Cardiac Surgeon) Dr Milan Chag (Cardiologist), Dr Chintan Seth and Dr Hiren Dholakia (Cardiac Anesthetists).



Healthy Heart Registered under **RNI No. GUJENG/2008/28043**

Published on 5<sup>th</sup> of every month

Permitted to post at PSO, Ahmedabad-380002 on the 12<sup>th</sup> to 17<sup>th</sup> of every month under  
Postal Registration No. **GAMC-1725/2015-2017** issued by SSP Ahmedabad valid upto 31<sup>st</sup> December, 2017  
Licence to Post Without Prepayment No. **CPMG/GJ/97/2014-15** valid upto 31<sup>st</sup> December, 2017

**If undelivered Please Return to :**

CIMS Hospital, Nr. Shukan Mall,  
Off Science City Road, Sola, Ahmedabad-380060.  
Ph. : +91-79-2771 2771-75 (5 lines)  
Fax: +91-79-2771 2770  
Mobile : +91-98250 66664, 98250 66668

**Subscribe "Healthy Heart"** : Get your "Healthy Heart", the information of the latest medical updates only ₹ 60/- for one year.  
To subscribe pay ₹ 60/- in cash or cheque/DD at CIMS Hospital Pvt. Ltd. Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060. Phone : +91-79-3010 1059 / 3010 1060. Cheque/DD should be in the name of : **"CIMS Hospital Pvt. Ltd."**  
Please provide your **complete postal address with pincode, phone, mobile and email id** along with your subscription



## WE THANK the medical fraternity for their continued support

**CIMS Hospital wins 2 awards at National Level New India Assurance  
Healthcare Achievers Awards 2014 An initiative by The Times of India**

**Trendsetter  
Award In Customer  
Service Excellence  
Across India**



**Best  
Multispeciality  
Hospital  
Ahmedabad**

CIMS Hospital : Regd Office: Plot No.67/1, Opp. Panchamrut Bungalows, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad - 380060.  
Ph. : +91-79-2771 2771-75 (5 lines) Fax: +91-79-2771 2770.

CIMS Hospital Pvt. Ltd. | CIN : U85110GJ2001PTC039962 | [info@cims.me](mailto:info@cims.me) | [www.cims.me](http://www.cims.me)

**Printed, Published and Edited by Dr. Keyur Parikh on behalf of the CIMS Hospital**

**Printed at Hari Om Printery, 15/1, Nagori Estate, Opp. E.S.I. Dispensary, Dudheshwar Road, Ahmedabad-380004.  
Published from CIMS Hospital, Nr. Shukan Mall, Off Science City Road, Sola, Ahmedabad-380060.**